medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 3

<< Back Next >>

Rev Invest Clin 2009; 61 (3)

Differences in inflammatory markers in a non-smoking and smoking Mexican population

Pérez-Bautista O, Ramírez-Venegas A, Escobar-Arriaga E, Sansores RH

Language: Spanish
References: 26
Page: 205-211
PDF size: 134.80 Kb.


ABSTRACT

Introduction. Cigarette smoking is one of the main risk factors for the development of cancer, chronic obstructive pulmonary disease and cardiovascular disease, most of which exhibit an inflammatory component at some stage of their time-course. However, little is known about the early presence of proinflammatory markers in healthy smokers. Material and methods.We conducted a 16-month, cross-sectional study to determine the presence of inflammatory markers in a group of smokers pronounced in good health after an exhaustive medical exam. Of an initial population of 1,806 smokers and non-smokers who underwent anthropometric, biochemical, radiographic and ultrasound studies plus exercise testing, 317 smokers and 297 non-smokers (the control group) found to have no alterations were ultimately selected and paired by age and gender. Their test data were then compared. Results. In comparison with non-smokers, smokers showed higher levels of C-reactive protein, hemoglobin, hematocrit, platelets, lipid profile and cardiovascular risk. They also showed lower values of total proteins, albumin and lactic dehydrogenase. Conclusions. Even though laboratory value results were considered to be within normal range, smokers showed increased levels of prothrombotic and proinflammatory molecules. Therefore, tobacco smoking can be considered an inflammatory syndrome whose final outcome could be one of the many organic disorders that characterize and accompany this entity.


REFERENCES

  1. Ezzati M, Henley SJ, Thun MJ, López AD. Role of smoking in global and regional cardiovascular mortality. Circulation 2005; 112: 489-97.

  2. Ezzati M, López AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-52.

  3. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005; 149: 606-12.

  4. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 1-13.

  5. Fowler-Brown A, Pignone M, Pletcher M, Tice JA, Sutton SF, Lohr KN. Exercise tolerance testing to screen for coronary heart disease: A systematic review for the technical support for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: W9-W24.

  6. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.

  7. Miller MR, Hankinson J, Brusasco V, et al. Standardization of spirometry. Eur Respir J 2005; 26: 319-28

  8. Aufweber E, Jorup-Ronstrom C, Edner A, Hansson LO. Creactive protein sufficient as screening test in bacterial vs. viral infections. J Infect 1991; 23: 216-20.

  9. Heatherton TF, Kozlowski TL, Frecker RC, Fagerström K. The Fagerström test for Nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991; 86: 1119-27.

  10. Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a national sample of U.S. adults: Results from the Second National Health and Nutrition Examination Survey Mortality Study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1052-6.

  11. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 2006; 166: 188-94.

  12. Shankar A, Klein BE, Klein R. Relation between white blood cell count and incident hypertension. Am J Hypertens 2004; 17: 233-9.

  13. Ohshita K, Yamane K, Hanafusa M, et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004; 27: 491-6.

  14. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women. Arch Intern Med 2005; 165: 500-8.

  15. Haim M, Boyko V, Goldbourt U, Battler A, Behar S. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease. Arch Intern Med 2004; 164: 433-9.

  16. Gawas M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-84

  17. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006; 81: 59-68.

  18. Irace C, Ciamei M, Crivaro A, et al. Hematocrit is associated with carotid atherosclerosis in men but not in women. Coron Artery Dis 2003; 14: 279-84.

  19. Kensey KR. The mechanistic relationships between hemorheological characteristics and cardiovascular disease. Curr Med Res Opin 2003; 19: 587-96.

  20. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl Med 2004; 350: 1387-97.

  21. Helzlsouer KR, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study. Eur J Cancer 2006; 42: 704-7.

  22. Sin DD, Man P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-9.

  23. Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004; 57: 195-202.

  24. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: Effects of aspirin treatment. Am Heart J 2005; 149: 832-9.

  25. Yasue H, Hirai N, Mizuno Y, et al. Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J 2006; 70: 8-13.

  26. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart Journal 2005; 26: 1765-73.




2020     |     www.medigraphic.com